Literature DB >> 7737902

Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.

Y Sasaki1, Y Yoshida, K Sudoh, H Hakusui, H Fujii, T Ohtsu, H Wakita, T Igarashi, K Itoh.   

Abstract

The pharmacokinetics of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), were examined to establish the pharmacokinetic variability of the active lactones of CPT-11 and SN-38 in comparison with that of the total (lactone and carboxylates) plasma CPT-11 and SN-38. Twelve patients with malignancies were entered in the study. All received 100 mg/m2 of CPT-11 by intravenous drip infusion over 90 min. Blood was sampled at 10 time points in heparin-containing syringes. Analysis by high-performance liquid chromatography showed that the ratio of CPT-11 lactone to total CPT-11 concentration was highest (66%) just after the end of infusion and gradually decreased to 30% at 24 h. Almost 70% of SN-38 lactone was detected after the end of infusion and this decreased to 50% within 24 h. The standard errors of percent lactone of CPT-11 of SN-38 to total drug concentration at each sampling point were less than 12%. The area under the concentration-time curve (AUC) of total CPT-11 and that of total SN-38 were significantly correlated with the AUCs of the lactone CPT-11 and those of lactone SN-38, respectively. We conclude that, for practical purposes, monitoring of total CPT-11 and SN-38 has essentially the same clinical significance as monitoring of lactone CPT-11 and SN-38.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737902      PMCID: PMC5920577          DOI: 10.1111/j.1349-7006.1995.tb02995.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  15 in total

1.  Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.

Authors:  R P Hertzberg; M J Caranfa; K G Holden; D R Jakas; G Gallagher; M R Mattern; S M Mong; J O Bartus; R K Johnson; W D Kingsbury
Journal:  J Med Chem       Date:  1989-03       Impact factor: 7.446

2.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

Authors:  J A Gottlieb; A M Guarino; J B Call; V T Oliverio; J B Block
Journal:  Cancer Chemother Rep       Date:  1970-12

3.  CPT-11 converting enzyme from rat serum: purification and some properties.

Authors:  T Tsuji; N Kaneda; K Kado; T Yokokura; T Yoshimoto; D Tsuru
Journal:  J Pharmacobiodyn       Date:  1991-06

4.  Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

Authors:  E K Rowinsky; L B Grochow; D S Ettinger; S E Sartorius; B G Lubejko; T L Chen; M K Rock; R C Donehower
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

5.  Phase I and pharmacokinetic trial of weekly CPT-11.

Authors:  M L Rothenberg; J G Kuhn; H A Burris; J Nelson; J R Eckardt; M Tristan-Morales; S G Hilsenbeck; G R Weiss; L S Smith; G I Rodriguez
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

6.  Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.

Authors:  S Negoro; M Fukuoka; N Masuda; M Takada; Y Kusunoki; K Matsui; N Takifuji; S Kudoh; H Niitani; T Taguchi
Journal:  J Natl Cancer Inst       Date:  1991-08-21       Impact factor: 13.506

7.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

Authors:  T Kunimoto; K Nitta; T Tanaka; N Uehara; H Baba; M Takeuchi; T Yokokura; S Sawada; T Miyasaka; M Mutai
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

8.  Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.

Authors:  N Kaneda; H Nagata; T Furuta; T Yokokura
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

9.  Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Authors:  E K Rowinsky; L B Grochow; C B Hendricks; D S Ettinger; A A Forastiere; L A Hurowitz; W P McGuire; S E Sartorius; B G Lubejko; S H Kaufmann
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.

Authors:  Y Sasaki; H Hakusui; S Mizuno; M Morita; T Miya; K Eguchi; T Shinkai; T Tamura; Y Ohe; N Saijo
Journal:  Jpn J Cancer Res       Date:  1995-01
View more
  9 in total

Review 1.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

2.  Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer.

Authors:  Hiroshi Imamura; Masataka Ikeda; Hiroshi Furukawa; Toshimasa Tsujinaka; Kazumasa Fujitani; Kenji Kobayashi; Hiroyuki Narahara; Michio Kato; Haruhiko Imamoto; Arimichi Takabayashi; Hideaki Tsukuma
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

3.  Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.

Authors:  Eric X Chen; Gerald Batist; Lillian L Siu; Naeema Bangash; Martha Maclean; Lynn McIntosh; Wilson H Miller; Amit M Oza; Chetan Lathia; Oana Petrenciuc; Lesley Seymour
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

4.  Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.

Authors:  Byung-Jin Ahn; Moon Ki Choi; Young Suk Park; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Jae-Wook Ko; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2010-09-09       Impact factor: 2.953

5.  Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.

Authors:  Y Sadzuka; S Hirotsu; S Hirota
Journal:  Jpn J Cancer Res       Date:  1999-02

Review 6.  Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

Authors:  Femke M de Man; Andrew K L Goey; Ron H N van Schaik; Ron H J Mathijssen; Sander Bins
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

7.  Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

Authors:  R H J Mathijssen; J Verweij; W J Loos; P de Bruijn; K Nooter; A Sparreboom
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

8.  A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.

Authors:  Y Sasaki; H Hakusui; S Mizuno; M Morita; T Miya; K Eguchi; T Shinkai; T Tamura; Y Ohe; N Saijo
Journal:  Jpn J Cancer Res       Date:  1995-01

9.  A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.

Authors:  Y Sasaki; S Mizuno; H Fujii; T Ohtsu; H Wakita; T Igarashi; K Itoh; I Sekine; Y Miyata; N Saijo
Journal:  Jpn J Cancer Res       Date:  1995-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.